Peptide Technical Analysis
TB-500 vs Thymosin Beta 4 Sequence: Lab Guide 2026
Compare TB-500 claims with the verified 43-residue thymosin beta 4 sequence, and learn which identity tests expose fragments, truncations, and substitutions.
“Is TB-500 the same as thymosin beta 4?” sounds like a simple catalog question. In practice, it is an identity-control problem. Thymosin beta 4, commonly abbreviated Tβ4, is a defined endogenous 43-amino-acid peptide. TB-500 is a market name used inconsistently across online catalogs. Some sellers use it as a synonym for synthetic full-length Tβ4; others describe it as a fragment or modified derivative without publishing a complete sequence. A purchase order carrying only “TB-500, 5 mg” does not define a chemical substance well enough for analytical release.
The typo “TB-50” appears in search queries and supplier listings, but it is not a recognized sequence designation. Buyers should not assume that the missing zero is harmless. A quotation, vial label, COA and test request all need the same unambiguous analyte name, sequence, terminal state, counterion and theoretical mass.
Full-length Tβ4 is more than the LKKTET motif
Human thymosin beta 4 is a 43-residue, N-terminally acetylated peptide. Its actin-binding behavior depends on distributed structural features, including an N-terminal helical region and the central LKKTET motif at residues 17–22. NMR and mutational studies have shown that the LKKTET segment participates in actin contact, but that does not make a six-residue motif equivalent to the full protein-derived peptide. Removing the flanking sequence changes molecular mass, charge, conformation, protease susceptibility and biological behavior.
This is where catalog language becomes unreliable. A seller may call a short actin-binding-region peptide “TB-500,” while another supplies a 43-residue material under the same name. There are also pages that repeat the assertion that TB-500 is a specific Tβ4 fragment but omit the actual amino-acid order. Without a sequence, there is no defensible theoretical mass and no way to design a selective LC-MS method. The appropriate database entry should therefore keep three fields separate: verified full-length thymosin beta 4; a vendor-defined TB-500 material with disclosed sequence; and an unknown TB-500 trade-name product awaiting structural assignment.
An intact mass matching full-length Tβ4 is useful but not conclusive. A sequence isomer can share the same elemental composition. Acetylation must also be addressed. If the theoretical mass was calculated for an unacetylated N-terminus while the reference is naturally acetylated, the result will differ by roughly 42 Da. Oxidation of methionine creates a roughly +16 Da shift, while deletion products show residue-specific deficits. Counterions and retained water affect gravimetric content but should not be mistaken for covalent sequence mass.
How to test a TB-500 lot
Start by refusing sequence-free specifications. Ask the supplier to provide one-letter and three-letter sequences, N- and C-terminal modifications, salt form, theoretical monoisotopic or average mass, and the basis for the “TB-500” name. Then compare the submitted data with a curated Tβ4 reference rather than another reseller page.
For full-length Tβ4, intact LC-HRMS confirms the mass envelope and exposes major truncations, oxidation and many adducts. A suitable RP-HPLC method estimates related-substance purity, although hydrophilic fragments may elute near the void and disappear from a poorly monitored integration window. Peptide mapping or MS/MS fragmentation provides sequence evidence. If a short fragment is claimed, direct tandem MS may offer strong coverage, but the analyst still needs standards or orthogonal confirmation for positional isomers and difficult leucine/isoleucine assignments.
- Reject any COA that lists “TB-500” without the tested sequence and terminal modifications.
- Recalculate theoretical mass independently and state whether the value is average or monoisotopic.
- Inspect the raw charge-state envelope and the deconvoluted spectrum, not a cropped single peak.
- Review the first minutes of the chromatogram for short, polar deletion products.
- Add oxidation monitoring, especially when methionine-containing full-length Tβ4 is claimed.
- Confirm peptide content by an appropriate quantitative method; area purity does not establish vial fill.
A frequent fraud pattern is a chromatogram from a cheap short peptide paired with a text-only claim for full-length Tβ4. Another is a “mass pass” based on one selected ion with no deconvolution or theoretical charge calculation. In both cases, the paperwork looks technical until the sequence and expected ions are placed beside the raw data.
Storage and sample preparation considerations
Full-length Tβ4 and short fragments should not automatically share a dissolution procedure. Sequence length and net charge affect solubility, adsorption and aggregation. Use the supplier’s verified sequence to estimate charge behavior, then run a small solubility check in the intended analytical matrix. Avoid forcing a stubborn sample into solution with a large pH jump before documenting recovery; the treatment can change the impurity profile. Low-binding vessels and controlled mixing reduce surface loss at dilute concentrations.
Keep lyophilized RUO material sealed, dry and light-protected at the temperature supported by that batch’s stability information. After dissolution, define hold time experimentally. Repeated freezing and thawing may increase oxidation or adsorption loss even if HPLC area purity appears stable. Include a time-zero control when investigating storage complaints.
Procurement language should identify the substance as “thymosin beta 4, full-length 43 aa, specified terminal state” when that is what the laboratory needs. If the project specifically requests TB-500, attach the vendor’s complete structural definition to the order and prohibit substitutions. Search PubMed for thymosin beta 4 actin binding, LKKTET structural requirements and Tβ4 peptide mass spectrometry to reach primary research rather than recycled catalog claims.
Current evidence does not support treating every TB-500 listing as one standardized analyte. The chemically honest answer is conditional: TB-500 may be marketed as Tβ4 or a related fragment, but identity depends on the disclosed structure and test data. This page concerns Research Use Only materials and does not provide instructions for human administration or therapeutic use.
Primary records and verification routes
Use the primary paper, current regulator record or lot-linked analytical file for the specific claim it supports. Search results are routes to evidence, not evidence by themselves.